← back to search

Xiaoli Bi

Guangzhou University of Chinese Medicine · CN
Area of research
Complementary and alternative medicine · Pharmacology
Research interest
Research interests include Chemistry, Pharmacology, Medicine, Chromatography, Pharmacokinetics, and Hyperlipidemia.
h-index
citations
219
works
24
NIH funding
primary concept
email

Recent publications

Integrated serum pharmacochemistry, pharmacokinetics, and network analysis to explore active components of BuShao Tiaozhi Capsule on hyperlipidemia
Frontiers in Pharmacology 2025cited by 4position: lastdoi
Mechanisms of Microctis Folium in Hyperlipidemia: Integrating Serum Pharmacochemistry, Network Pharmacology, and Transcriptomics
Drug Design Development and Therapy 2025cited by 2position: lastdoi
Corrigendum to “A novel quantification method of lung fibrosis based on Micro-CT images developed with the optimized pulmonary fibrosis mice model induced by bleomycin” [Heliyon Volume 9, Issue 3, March 2023, Article e13598]
Heliyon 2025cited by 2position: middledoi
Integrating network toxicology and molecular docking to explore the toxicity of the environmental pollutant butyl hydroxyanisole: An example of induction of chronic urticaria
Heliyon 2024cited by 17position: lastdoi
Comparison of ELSD and RID combined with HPLC for simultaneous determination of six rare sugars in food components
Microchemical Journal 2024cited by 17position: middledoi
Investigation into the anti-inflammatory mechanism of Pothos chinensis (Raf.) Merr. By regulating TLR4/MyD88/NF-κB pathway: Integrated network pharmacology, serum pharmacochemistry, and metabolomics
Journal of Ethnopharmacology 2024cited by 16position: lastdoi
ESL attenuates BLM-induced IPF in mice: Dual mediation of the TLR4/NF-κB and TGF-β1/PI3K/Akt/FOXO3a pathways
Phytomedicine 2024cited by 16position: lastdoi
Metabolomics and network pharmacology reveal partial insights into the hypolipidemic mechanisms of ferulic acid in a dyslipidemia mouse model
Frontiers in Pharmacology 2024cited by 3position: lastdoi
A novel quantification method of lung fibrosis based on Micro-CT images developed with the optimized pulmonary fibrosis mice model induced by bleomycin
Heliyon 2023cited by 16position: middledoi
Metabolomics analysis delineates the therapeutic effects of Yinlan Tiaozhi capsule on triton WR-1339 -induced hyperlipidemia in mice
Frontiers in Pharmacology 2023cited by 12position: lastdoi
Integrated network pharmacology and metabolomics reveal the mechanisms of Jasminum elongatum in anti-ulcerative colitis
Scientific Reports 2023cited by 12position: middledoi
Deciphering the mechanisms of Yinlan Tiaozhi capsule in treating hyperlipidemia by combining network pharmacology, molecular docking and experimental verification
Scientific Reports 2023cited by 11position: lastdoi
Selection and evaluation of biomarkers of Gynostemma pentaphyllum (Thunb.) Makino representing its tonifying weakness and strengthening muscle effect based on PXR/IL-6/SERCA1a regulation
Arabian Journal of Chemistry 2023cited by 2position: middledoi
[Prediction and analysis of Q-markers of Elephantopus scaber based on its UPLC fingerprint, content determination of components, and in vitro a nti-tumor activity].
PubMed 2023cited by 2position: lastdoi
Network pharmacology analysis and experimental validation to explore the mechanism of Bushao Tiaozhi capsule (BSTZC) on hyperlipidemia
Scientific Reports 2022cited by 19position: lastdoi
Metabolic Insight Into the Neuroprotective Effect of Tao-He-Cheng-Qi (THCQ) Decoction on ICH Rats Using Untargeted Metabolomics
Frontiers in Pharmacology 2021cited by 15position: middledoi
The anti-hyperlipidemia effect of Yinlan capsule via regulation of PXR activity
Phytomedicine Plus 2021cited by 5position: middledoi
Corrigendum to “Selection of quality markers of Jasminum amplexicaule based on its anti-diarrheal and anti-inflammatory activities: Effect-target affiliation-traceability-pharmacokinetics strategy” [Chinese Herbal Medicines 11 (2019) 379–386]
Chinese Herbal Medicines 2021cited by 1position: middledoi
Selection and evaluation of quality control markers in propolis based on its hyperlipidemia therapy via regulating PXR/CYP3A4 expression
Phytomedicine Plus 2020cited by 7position: middledoi
Selection and evaluation of quality markers from Yinlan capsule and its LXRα-mediated therapy for hyperlipidemia
Phytomedicine 2019cited by 11position: middledoi
Selection of quality markers of Jasminum amplexicaule based on its anti-diarrheal and anti-inflammatory activities: Effect-target affiliation-traceability-pharmacokinetics strategy
Chinese Herbal Medicines 2019cited by 3position: middledoi
Pharmacokinetic based study on “lagged stimulation” of Curcumae Longae Rhizoma - Piper nigrum couplet in their main active components’ metabolism using UPLC-MS-MS
Phytomedicine 2017cited by 22position: middledoi
A fast and accurate method for the pharmacokinetic research of four coumarin analogs in <i>Fructus cnidii</i> using capillary electro‐chromatography with a methacrylate ester‐based monolithic column
Electrophoresis 2017cited by 4position: middledoi
Study on HPLC-fingerprint of Microcos paniculata
Zhongguo shiyan fangjixue zazhi 2012cited by 0position: first

Grants

No grants ingested yet.

Frequent collaborators

Guanlin Xiao · Guangzhou University of Chinese Medicine13 papers (2020–2025)Dake Cai · Guangzhou University of Chinese Medicine8 papers (2017–2024)Yangxue Li · Jilin University8 papers (2022–2025)Zhihao Zeng · Guangzhou University of Chinese Medicine8 papers (2022–2025)Dongmei Sun · Guangzhou University of Chinese Medicine8 papers (2017–2021)Xu Aili · Guangzhou University of Chinese Medicine8 papers (2017–2023)Sumei Li · First People's Hospital of Nanning7 papers (2021–2025)Dezheng Jia · Guangzhou University of Chinese Medicine6 papers (2023–2025)Canhui Xie · Guangzhou University of Chinese Medicine5 papers (2023–2024)Canchao Jia · Guangzhou University of Chinese Medicine5 papers (2023–2025)Yanchang Liu · Guangzhou University of Chinese Medicine4 papers (2024–2025)Minjuan Yang · Guangzhou University of Chinese Medicine4 papers (2023–2024)Zhao Chen · University of Arizona4 papers (2022–2023)Guangying Wu · Guangzhou University of Chinese Medicine4 papers (2023–2025)Wenhui Luo · Guangzhou University of Chinese Medicine4 papers (2017–2020)Li-Zhong Cao · Guangzhou University of Chinese Medicine3 papers (2019–2021)Xuejun Huang · Guangzhou University of Chinese Medicine3 papers (2023–2025) · 3 papers (2022–2024)Zhao Chen · Harbin Medical University3 papers (2019–2021)Weitao Chen · Guangzhou University of Chinese Medicine3 papers (2019–2021)